Literature DB >> 37872

Possible significance of the pharmacological differentiation of beta-blockers for therapy of hypertension.

F H Leenen.   

Abstract

1 Cardioselective and non-selective beta-blockers affect to a different degree several aspects of the circulatory homeostasis. The evidence available in this regard has been evaluated and the possible clinical importance of these differences has been discussed. 2 Venous return in partly regulated by beta-receptors (possibly of the beta 2 type) in the venous resistance vessels. Differences in blockade of venous return by the two classes of beta-blockers may, therefore, influence the degree of increase in left ventricular size, left ventricular end diastolic BPs and stroke volume during beta-blockade. 3 At the first part of the dose-reponse curve, non-selective beta-blockers seem to block more effectively renin release than cardioselective beta-blockers. 4 The direction and the extent to which beta-blockers 'directly' affect total peripheral resistance (TPR), is determined by the resultant of the degree of decrease in TPR by blockade of renin release and the extent of the increase in TPR by blockade of the beta 2-receptors in the arteriolar wall. 5 The clinical relevance of these differences could be that--especially in the low doses range--non-selective beta-blockers may be more 'safe' in patients with compromised cardiac function and may be more appropriate for the therapy of high renin hypertension than cardioselective blockers, whereas the latter may be more appropriate for the majority of hypertensive patients who have low to normal renin hypertension.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37872      PMCID: PMC1429316          DOI: 10.1111/j.1365-2125.1979.tb04688.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Long term non-selective and cardioselective beta-receptor blockade in hypertensive patients. Effects on circulatory parameters, catecholamines and renin activity under basal conditions and in connection with exercise and hypoglycemia.

Authors:  B G Hansson
Journal:  Acta Med Scand Suppl       Date:  1976

2.  Alpha and beta adrenergic-induced renin release in man.

Authors:  F H Leenen; D P Redmond; R H McDonald
Journal:  Clin Pharmacol Ther       Date:  1975-07       Impact factor: 6.875

3.  Pressure-flow relationships in the peripheral circulation of the dog with isoprenaline.

Authors:  J F Green
Journal:  Clin Exp Pharmacol Physiol       Date:  1975 Mar-Apr       Impact factor: 2.557

Review 4.  The renin-angiotensin system.

Authors:  I A Reid; B J Morris; W F Ganong
Journal:  Annu Rev Physiol       Date:  1978       Impact factor: 19.318

5.  Beta-blockers and asthma.

Authors:  P B Decalmer; S S Chatterjee; J M Cruickshank; M K Benson; G M Sterling
Journal:  Br Heart J       Date:  1978-02

6.  The effect of mental arithmetic in normotensive and hypertensive subjects, and its modification by beta-adrenergic receptor blockade.

Authors:  G Nyberg; R M Graham; G S Stokes
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

7.  Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.

Authors:  R G Wilcox
Journal:  Br Med J       Date:  1978-08-05

8.  Effects of beta adrenergic blockade on plasma catecholamines in exercise.

Authors:  M H Irving; B J Britton; W G Wood; C Padgham; M Carruthers
Journal:  Nature       Date:  1974-04-05       Impact factor: 49.962

9.  Pressure-flow relationships in the peripheral circulation of the dog with practolol.

Authors:  J F Green; J D Moore; E S Attix; R Zelis
Journal:  Clin Exp Pharmacol Physiol       Date:  1975 Jan-Feb       Impact factor: 2.557

10.  Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.

Authors:  D B Case; J M Wallace; H J Keim; J E Sealey; J H Laragh
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

View more
  2 in total

1.  Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography.

Authors:  S H Thomas; R C Cooper; M Ekwuru; S Fletcher; J Gilbody; T S Husseyin; M Ishaque; R Jagathesan; G Reddy; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.

Authors:  Jasmina Varagic; Henry Punzi; Carlos M Ferrario
Journal:  Integr Blood Press Control       Date:  2014-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.